Futura Medical has received regulatory clearance to launch its stronger Eroxon Intense erectile dysfunction gel across the European Economic Area and the UK. This approval follows successful design, validation, and pre-market work under existing European CE and UKCA certifications. The product, which offers a faster and stronger effect than the original Eroxon, showed promising results in a home-user test with 223 men. Futura expects US FDA clearance in the second half of 2026, aiming for a US launch in 2027 with its commercial partner MPG.
Novo Nordisk announced that its ZEUS phase 3 trial testing ziltivekimab, an IL-6 pathway inhibitor, in over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation did not reduce major adverse cardiovascul...
Perella Weinberg Partners reported Q2 2026 revenues of $157 million, a 1% increase from last year, with adjusted pre-tax income of $27 million and adjusted EPS of $0.20. Despite a 17% revenue decline in the first half of 2026, the firm is investing i...
Perella Weinberg Partners announced the promotion of eight managing directors to partners, recognizing their achievements and leadership in sectors like financial services, healthcare, and capital solutions. This move highlights the firm's confidence...
Artem Voinov, Chief Business Development Officer at ICODA, will attend Blockchain Rio 2026, Latin America's largest blockchain conference, held August 12–13 in Rio de Janeiro. The event gathers regulators, financial institutions, and Web3 leaders, em...
Palantir reported that its profit nearly quadrupled over the past year, signaling strong financial growth. Despite this, the company's stock price has fallen 40% from its highest point, reflecting market concerns or volatility. Both the profit figure...
